Skip to main content

IXAZOMIB

Tracking # 20-810555

$99999.00

There are no ratings for this course

Learn more
CE Broker Reporting Reported automatically
Method Computer-Based Training

Course overview

IXAZOMIB, A SECOND-GENERATION PROTEASOME INHIBITOR, IS USED PRIMARILY IN THE TREATMENT OF MULTIPLE MYELOMA. THIS ACTIVITY OUTLINES THE MECHANISM OF ACTION, INDICATIONS, AND CONTRAINDICATIONS FOR IXAZOMIB AS A VALUABLE AGENT IN TREATING MULTIPLE MYELOMA. THIS ACTIVITY WILL HIGHLIGHT THE MECHANISM OF ACTION, ADVERSE EVENT PROFILE, AND OTHER KEY FACTORS PERTINENT FOR MEMBERS OF AN INTERPROFESSIONAL TEAM MANAGING THE CARE OF PATIENTS WITH MULTIPLE MYELOMA AND ITS RELATED CONDITIONS AND SEQUELAE.

Subject areas

This course counts toward the state boards and subject areas below.

Bahamas Medical Council

Specialty Medical Practitioner

1h General Medicine

Louisiana State Board of Medical Examiners - Physicians & Surgeons

Physician & Surgeon

1h Category I CME

Mississippi State Board of Medical Licensure

Medical Doctor

1h AMA Category I

Physician Assistant

1h AMA Category I

State Medical Board of Ohio

Doctor of Medicine

1h AMA Category I